April 2009

April 2009 Supplement

Articles

UP FRONT

CATARACT SURGERY

COVER STORIES

TODAY'S PRACTICE

DEPARTMENTS

View All News >
News
Conflicting Views About Collagen Crosslinking Therapy

Treating keratoconus with UV-A light and riboflavin to crosslink corneal collagen is a noninvasive and relatively inexpensive procedure. Clinical studies with 3- to 5-year follow-up after corneal collagen crosslinking (CXL) th... more >

News
Alcon Received Aspheric Toric IOL Approval, Signed Contract With LCA Vision

The FDA approved the AcrySof IQ Toric IOL (Alcon, Inc., Huenenberg, Switzerland). According to a company news release, the acrylic one-piece lens offers an enhanced aspheric optic that improves image quality and increases contrast... more >

News
Bausch & Lomb Signed Two Industry Agreements

Bausch and Lomb (Rochester, New York) and Pfizer Inc. (New York, New York) will copromote both companies' prescription ophthalmic drugs in the United States. Under a 5-year agreement, both company's sales forces will promote Pfize... more >

News
AMO Renamed Abbott Medical Optics, Inc.

Abbott (Abbott Park, Illinois) completed its acquisition of Advanced Medical Optics, Inc. (AMO; Santa Ana, California). AMO is now a wholly owned subsidiary of Abbott and has been renamed Abbott Medical Optics, Inc. In ... more >

TOP 5 ARTICLES FROM APRIL 2009

  • Special Considerations in Combined Cataract Surgery, DSAEK

    In combination with cataract removal, special care is needed for DSAEK, but the procedure does convey advantages.

    by W. Barry Lee, MD, FACS

  • Is CXL an Alternative to Keratoplasty?

    CXL may postpone or prevent corneal transplantation in patients with progressive keratoconus or pellucid marginal degeneration.

    by Josef Reiter, MD

  • ICRS Plus Crosslinking

    This combination results in greater improvements versus Keraring implantation alone.

    by Efekan Coskunseven, MD; Mirko R. Jankov II, MD, PhD; and George D. Kymionis, MD, PhD

  • PRK Followed by CXL

    This treatment improves functional vision and reduces the need for keratoplasty.

    by George D. Kymionis, MD, PhD; Georgios A. Kontadakis, MD, MSc; Dimitra M. Portaliou, MD; and Ioannis G. Pallikaris, MD, PhD

  • CXL Indications and Patient Selection

    Patients must be told that the goal of treatment is not a refractive endpoint.

    by Richard Corkin, FCS (Ophth)SA, MRCOphth